top of page
  • Active, not recruiting

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors

Updated: Jun 27, 2022

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors


tti-622 trillium

NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors


Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.


Sponsor

Trillium Therapeutics Inc.

 

ClinicalTrials.gov Identifier: NCT02663518

Official Title: A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

First Posted : January 26, 2016

Click here to see details on ClinicalTrials.gov

 

Drug: TTI-621

Drug: TTI-621 plus Rituximab

Drug: TTI-621 plus Nivolumab

 

TTI 621

Ontorpacept (Code C125718)

Ontorpacept

ONTORPACEPT

SIRPa-Fc Fusion Protein TTI-621

SIRPaFc

TTI 621